A cDNA encoding NF-IL6, an interleukin-6 (IL-6)-regulated human nuclear factor of the C/EBP family, is demonstrated to complement the transactivation function of EIA. The endogenous NF-IL6 level varies according to cell type and correlates positively with an IL-6-regulated cellular ElA-substituting activity that was described recently (J. M. Spergel and S. Chen-Kiang, Proc. Natl. Acad. Sci. USA 88:6472-6476, 1991). When expressed by transfection in cells which contain low levels of NF-IL6 and are incapable of complementing the function of ElA proteins, NF-IL6 also transactivates the ElA-responsive E2ae and ElB promoters, to the same magnitude as ElA. Activation by NF-IL6 is concentration dependent and sequence specific: mutational studies of the E2ae promoter suggest that the promoter-proximal NF-IL6 recognition site functions as a dominant negative regulatory site whereas the promoter-distal NF-IL6 recognition site is positively regulated at low NF-IL6 concentrations and negatively regulated when the NF-IL6 level is high. Consistent with these functions, NF-IL6 alone is sufficient to complement an EIA deletion mutant d1312 in viral infection, when expressed at appropriate concentrations. These results identify NF-IL6 as a sequence-specific cellular nuclear factor which regulates ElA-responsive genes in the absence of ElA.
The polypeptides encoded by the transforming gene ElA of adenovirus transactivate all early genes of the virus, as well as a subset of cellular genes, and repress simian virus 40, immunoglobulin heavy chain, and insulin enhancerlinked promoters (for a review, see references 3, 17, and 58). Although structural analyses have yielded insights into domains important for the multiple functions of the ElA gene products (48) , the molecular mechanism of ElA action has remained elusive. It has been suggested that ElA proteins function in synergy with cyclic AMP (cAMP) (16, 43, 49) ; through TFIID (34, 68) or ATF-2 (44) ; or by sequestering repressors in the cell (2) . ElA also enhances RNA polymerase III transcription by activating transcription factor IIIC (28) . The complexity of delineating the mechanism of ElA action is at least in part due to its ability to induce some promoters and not others, without apparent sequence specificity. Furthermore, it functions in a highly cell type-specific manner as a transactivator or repressor with respect to the same immunoglobulin heavy-chain enhancer in different cells (5, 25) . Although many cellular proteins are associated with the ElA polypeptides, most notably the retinoblastoma gene products (67) and cyclins (21) , the putative cellular repressor has not yet been identified.
A cellular activity (or activities) which functionally substitutes for ElA in transactivating an ElA-responsive adenovirus E2ae promoter has been shown to be present in mouse embryonal carcinoma cells (31, 39) , in oocytes, and during early development in preimplantation embryos (15) . Its identity, however, has remained obscure. A functionally related cellular activity was recently found in HepG2 cells, a human hepatoblastoma cell line. In addition to the E2ae promoter, the ElA-responsive E1B promoter was active in HepG2 cells in the absence of ElA, when assayed by either * Corresponding author.
transfection or viral infection. Furthermore, HepG2 cells supported productive infection of ElA deletion mutant virus. Unlike the activity in mouse embryonal carcinoma cells, which diminishes upon cellular differentiation, the E1A-substituting activity in HepG2 cells increases dramatically upon induction by the cytokine interleukin-6 (IL-6), resulting in full complementation of infection of ElA deletion viruses (64) .
The enhancement of the ElA-substituting activity in HepG2 cells by IL-6 suggests that a nuclear factor(s) regulated by or transducing the IL-6 signal may mediate, or in itself be, the cellular activity which functionally substitutes for ElA. IL-6 is a multifunctional cytokine which promotes growth, inhibits growth, and induces differentiation in a highly cell-type-specific manner (for a review, see reference 27) . Among its many differentiation functions, IL-6 promotes terminal differentiation of human B cells by coordinate activation of immunoglobulin heavy-and light-chain genes at the level of transcription (57) . Although the IL-6 signal transduction pathway is largely unknown, NF-IL6, a human nuclear factor which is regulated by IL-6, has recently been cloned and found to belong to the C/EBP leucine zipper family (1) . It 
MATERIALS AND METHODS
Cells and viruses. HepG2 cells, a human hepatoblastoma cell line (35) , were cultured in Eagle's minimal essential medium. Jurkat cells, a human T-cell line, were cultured in RPMI 1640. All media were supplemented with 10% heatinactivated fetal calf serum L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 ,xg/ml), and nonessential amino acids (GIBCO). Infections and propagation of adenovirus type 2 (Ad2) and d1312 were performed as described previously (40) . HepG2 cells were induced with 500 U of IL-6 per ml (57) .
Plasmids and oligonucleotides. Plasmid 4xNF-IL6pA1O-CAT contains four copies of the NF-IL6 responsive element [5'-GATC(ACATTGCACAATCT)4-3'] 5' to an enhancerless simian virus 40 promoter linked to the reporter CAT gene (32) . The pE2ae-CAT plasmid contains 346 bp of the Ad5 E2ae promoter (from -284 to +62) cloned into pSVO-CAT. Linker-scanning (LS) mutants of E2 are as described previously (50) . pAd5E1A contains bp 1 to 1764 of the adenovirus type S genome and expresses all three ElA proteins (65) . The pElB-CAT plasmid contains the promoter region of E1B from -365 to +1 (13) . The positive control for transfection, pRSV-CAT, contains a 524-bp fragment (PvuII site to BstNI site) of the 3' long terminal repeat of Rous sarcoma virus (RSV) (22) . The negative control, pJYM-CAT, contains the simian virus 40 TATA box but no enhancer (45) .
RSV-,Bgal contains the P-galactosidase gene driven by the RSV long terminal repeat enhancer-promoter (4). pCMV-NF-IL6(+) contains a cDNA encoding NF-IL6 directed by the cytomegalovirus promoter, and pCMV-NF-IL6(-) is its antisense derivative (1) .
Synthetic DNA oligonucleotides were prepared by using an automated DNA synthesizer (Applied Biosystems, Inc.) and purified by electrophoresis in a 8 M urea-12% polyacrylamide gel. DNA was eluted in a buffer consisting of 0.1 M NaCl, 10 mM Tris-Cl (pH 7.4), and 1 mM EDTA; bound to a NENSORB column (New England Nuclear); and subsequently eluted in 50% methanol. The eluted DNA was dried under vacuum, dissolved in H20, and quantified by its A260 Double-stranded oligonucleotides were 5' end labeled with T4 DNA polynucleotide kinase and [y-32P]ATP under standard conditions (61) .
DNA probes used are as follows (the core recognition sequence of each DNA probe is underlined). 20, 40, 60, 120 , and 180 min of incubation. The slope of the organic-miscible radioactivity as a function of time was calculated and used to represent the CAT activity (53, 61) , the slope of the RSV CAT activity was used as a positive control, and the slope of the JYM CAT activity was used as a negative control:
Electrophoretic mobility shift assay. Nuclear extracts were prepared at 4°C essentially as described by Mattila et al. (47) . The protein concentration was determined by the Bradford assay (6) with a protein assay kit (Bethesda Research Laboratories). The mobility shift assays were based on the methods of Fried and Crothers (18) and Gamer and Revzin (20) . Nuclear extract (2 to 3 ,ug) was used for binding in a buffer containing 5 mM Tris-Cl, 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.9), 50 mM NaCI, 1 mM dithiothreitol, 10% glycerol, and 1 ,ug of poly(dI-dC) (Boehringer Mannheim Biochemicals) to 1 ng of the NF-IL6 probe in the presence of 15 mM EDTA. Competition with oligonucleotides, at a 100-fold molar excess, and preincubation with antibodies were performed by incubation of extracts with oligonucleotides or antibodies at room temperature for 10 min. The probe was then added, and the mixture was incubated for 20 min. The bound DNA was separated from the free DNA by electrophoresis on a 6% nondenaturing polyacrylamide gel, unless otherwise indicated, in 0.25x TBE (18 mM Tris base, 18 mM borate) at 250 V at 4°C. The gels were transferred to dampened DEAE 81 (DE81; Whatman), dried, and exposed to X-OMAT film.
Other assays. For the RNase protection assay, poly (A)'
RNAs were isolated and selected as previously described (40) and the assay was carried out as described by Marton et al. (46) . For the immunofluorescence assay, indirect immunofluorescence microscopy was performed essentially as previously described (40) with a monoclonal antibody directed toward the adenovirus E2 72-kDa protein (72K protein) as the first antibody and fluorescein isothiocyanateconjugated sheep anti-mouse immunoglobulin as the second antibody.
Antibodies and recombinant proteins. Polyclonal antisera directed against peptide 3 of NF-IL6 (a-NF-IL6 [1] ), against recombinant LAP (a-LAP; kindly provided by U. Schibler [14] ), and against a 14-amino-acid unique peptide of C/EBP (a-14; kindly provided by S. McKnight [37] ) and monoclonal antibodies directed against the adenovirus E4 ORF6/7 polypeptide (a-E4; kindly provided by T. Shenk [46] ) and against the adenovirus E2 72K protein (kindly provided by R.
A.
HepG2
JKrrLAP Carrol) were used as indicated. Purified recombinant LAP protein (14) was kindly provided by U. Schibler.
RESULTS
The NF-IL6-binding activity correlates with the endogenous ElA-substituting activity. The marked enhancement of a cellular activity in HepG2 cells by IL-6 (64) and the lack of this activity in other human cells, including lymphoid cells which require very low levels of ElA for productive infection (41), suggest that a cellular factor regulated by IL-6 may functionally substitute for ElA. This hypothesis predicts that if NF-IL6 represents an ElA-substituting activity, its level may be cell type specific. This was shown to be the case. Binding of proteins in nuclear extracts of HepG2 cells to a synthetic oligonucleotide containing a NF-IL6 recognition sequence, 5'-AGATTGTGCAACT-3', was 15 to 20-fold greater than binding of protein in nuclear extracts of Jurkat cells to the same DNA probe, as assayed by the electrophoretic mobility shift assay (Fig. 1A) . Jurkat cells do not express the 80-kDa IL-6 receptor (69) or an ElA-substituting activity, but can support productive adenovirus infection in the presence of ElA (40) .
In agreement with regulation of both NF-IL6 (1) and an ElA-substituting activity (64) in HepG2 cells by IL-6, the formation of DNA-protein complexes was increased two to threefold in extracts prepared after IL-6 induction. The complexes formed were specific, since they were not inhibited by DNA of unrelated sequences, and they comigrated with those formed with recombinant LAP (rLAP), a reference protein, on the same NF-IL6 probe. LAP (14) , also known as IL-6 DBP and AGP/EBP (10, 54) , is a rodent transcription factor of the C/EBP family that is inducible by IL-6 (54). Highly homologous in its amino acid sequence and almost identical in its DNA-binding and leucine zipper domains to NF-IL6, it is most probably the rat homolog of human NF-IL6 (Fig. 1C) .
Consistent with these results, a-NF-IL6, an antiserum which recognizes NF-IL6, inhibited binding. So did a-LAP, an antiserum directed against recombinant LAP; however, a-E4, a control antibody directed against the 19-kDa polypeptide product of the adenovirus E4 gene, and a14, a peptide antiserum specific for the rat C/EBP, did not. In fact, al4 reproducibly enhanced protein-NF-IL6 complex formation (Fig. 1B) (1, 14) . The NF-IL6 recognition sequence is present in the promoters of nearly all E1A-responsive viral and cellular genes. The mechanism of transactivation of ElA-responsive genes by NF-IL6 is therefore unlikely to be the same as that of ElA activation. Since NF-IL6 binding activity was dramatically reduced in both HepG2 and Jurkat cells after virus infection, when the ElA-responsive promoters were active (Fig. 1A) , it is also unlikely that NF-IL6 serves as an obligatory intermediate for the transactivation function of ElA.
To investigate whether NF-IL6 activates ElA-responsive genes at the level of transcription initiation, pCMV-NF-IL6 (+), an expression vector of NF-IL6, was cotransfected with pE1B-CAT or pE2ae-CAT (E1B or E2ae promoters, respectively, linked to the CAT reporter gene) into HepG2 and Jurkat cells (Fig. 2) . It is clear that when expressed at lower concentrations [1 to 5 ,ug of pCMV-NF-IL-6(+) transfected into 106 cells], NF-IL6 transactivated E2ae and E1B promoters in both cell lines (Fig. 2B and C) . The increases of E2ae and E1B promoter activates by NF-IL6, 15 -to 20-fold in Jurkat cells and 2-to 4-fold in HepG2 cells, appeared to be inversely correlated with the basal promoter activities in these cell lines. Furthermore, in Jurkat cells the levels of transactivation of these promoters by NF-IL6 approached those seen with ElA proteins, expressed by cotransfecting pAd5E1A (Fig. 2C and D) . However, whereas transactivation by ElA did not diminish significantly at higher ElA protein concentrations, NF-IL6 at concentrations above a threshold had a markedly reduced ability to transactivate both promoters (Fig. 2C and D) .
Thus, although the magnitude of transactivation by NF-IL6 is cell type dependent, NF-IL6 can transactivate E1A-responsive promoters in transfection, contingent upon its concentration and to levels comparable to those for transactivation by ElA proteins.
NF-IL6 functions as a negative or positive regulator in a site-specific and concentration-dependent manner. Nuclear factors of the C/EBP family are known to bind to specific DNA sequences in dimerized form with various affinities (14, 38, 59) , and LAP can dimerize with C/EBP (14) . Since dimerization is concentration dependent, it raises the possibility that formation of specific NF-IL6-promoter complexes and the promoter activity depends upon endogenous levels of NF-IL6 and the DNA sequences to which NF-IL6 binds. Two NF-IL6 recognition elements are present in the E2ae promoter, at -46 and -69 (designated as NF-IL6 and NF-IL6* sites respectively [ Fig. 3A] ). The NF-IL6* site overlaps with an ATF recognition element to which members of the AP-1 family can also bind, albeit with reduced relative affinity (51, 56) . One of them, junB, has been shown to be regulated by IL-6 signaling (52).
The functional significance of NF-IL6 and NF-IL6* sites in the E2ae promoter was explored by cotransfecting linkerscanning (LS) mutants of the E2ae promoter with the NF-IL6 expression vector, pCMV-NF-IL6(+), or its antisense derivative, pCMV-NF-IL6(-), into Jurkat and HepG2 cells (Fig. 3) . In Jurkat cells, in the absence of additional NF-IL6, transcription from the E2ae promoters of LS mutants -40/ -50 and -49/-59, in which the NF-IL6 site (-46 to -54) was mutated, was 10-to 20-fold greater than that from the wild-type E2ae promoter (Fig. 3B) A. pression by alteration of the NF-IL6 site, as displayed by the LS -49/-59 mutant, ranged from 10-to 25-fold in seven transfection experiments and was not influenced by the presence of the cotransfected pCMV-NF-IL6(-) (Fig. 3B  and 4A ). This result is reminiscent of an earlier observation in HeLa cells, in which LS -49/-59 exhibited a fivefoldgreater promoter activity than the wild-type promoter (50) . Derepression was not exhibited by LS mutant -63/-72 or -74/-85, in which the NF-IL6* site was mutated (Fig. 3B) . These results suggest that the two NF-IL6 recognition sites differ in their functions: the NF-IL6 site functions primarily as a dominant negative regulatory site, while the NF-IL6* site is necessary for transactivation.
It was also apparent that derepression was insignificant in HepG2 cells, which express a high level of endogenous NF-IL6-binding activity (Fig. 1) and form additional E2ae promoter complexes in reference to Jurkat cells in vitro (28a) . When (33) .
Indirect immunofluorescent staining of the 72K singlestranded DNA-binding protein, encoded by the viral transcription unit E2ae which is dependent on ElA for activation and is essential for viral replication, showed that expression of NF-IL6 led to the synthesis of the 72K protein in the absence of ElA (Fig. 5) . Complementation of the ElA transactivation function by NF-IL6 appeared to be efficient and specific. Synthesis of the 72K protein either in the presence of ElA in wild-type infection or in cells transfected with NF-IL6 prior to infection with dl312 was comparable, at 2 days after viral infection prior to the onset of viral replication, in approximately 15% of cells (Fig. 5) . In cells infected with d1312 alone or transfected with the antisense derivative of NF-IL6 pCMV-NF-IL6(-) prior to infection with d1312, the 72K protein was undetectable.
Similarly, NF-IL6 activates the E1B transcription unit, which is also dependent on ElA for activation in viral infection. RNase protection assays demonstrated that expression of NF-IL6 in the absence of ElA resulted in the accumulation of E1B mRNAs to the wild-type level, albeit delayed by 1 day after viral infection (Fig. 6) . The protected RNAs corresponding to the positive controls, the common 3' exon, and the 5' exons of alternatively spliced ElA 13S and 12S mRNAs were also evident in wild-type virus-infected cells, but not in NF-IL6-transfected dl312-infected cells. Likewise, control cells infected with dl312, with or without transfection of the antisense construct of NF-IL6, showed no synthesis of ElA and E1B mRNA (Fig. 6) .
Previously, we have shown that IL-6 signaling enhanced an ElA-substituting activity in HepG2 cells which led to a greater than 30-fold increase in the steady-state E1B and E2ae mRNA levels in viral infection in the absence of ElA (64 (Fig. 1A) . The reduction of NF-IL6 activity is most probably due to modification or regulation of NF-IL6 by ElA, since it occurs early after infection, before virus induced host protein synthesis shutoff takes place (28a) (Fig. 1A) . How (9) and in mouse liver after injection of the mouse with IL-6 (32) .
Third, the NF-IL6* site may be functionally redundant, allowing NF-1L6 to function cooperatively and competitively with members of the AP-1 or ATF transcription factor families. This view is supported by our results that in the absence of the dominant negative regulatory NF-IL6 site, LS mutants -49/-59 and -40/-50 were active in the presence of a level of NF-1L6 otherwise inadequate for transactivation ( Fig. 3B and 4A) . Together with the possibility that NF-IL6 cooperates with members of the AP-1 family and possibly also of the ATF family, in forming specific E2 promoter complexes (65) , it is reasonable to speculate that in the absence of NF-IL6 after viral infection, some members of the AP-1 or ATF family may gain entry to the NF-IL6* site and activate transcription of the promoter. In this manner, ElA may function to modify and reduce NF-IL6 on the one hand and to increase the activities of activators such as AP-1 or ATF on the other hand, thereby sequestering a cellular pathway. In the presence of ElA, the presence of a dominant negative regulatory site, such as the NF-IL6 site at the E2ae promoter, provides an additional constraint in regulation but need not be obligatory.
This possiblity is consistent with the results of Muller et al. (49) , who showed that cAMP functions synergistically with ElA in transactivating ElA-responsive promoters during viral infection, possibly through c-fos and junB, whose syntheses are regulated by ElA (49, 66) . It is also in agreement with the observations that nuclear factors of the ATF/CREB family can participate in or mediate the ElA transactivation function (7, 24, 30, 42-44, 60, 63 The biological significance of regulation of ElA-responsive genes by the IL-6 signal transduction pathway. What is the biological significance of regulating ElA-responsive genes by the IL-6 signal transduction pathway? The NF-IL6 recognition sequence is present in many viral enhancers and promoters, among them the transforming gene E1B, which, in the viral chromosome, is regulated by NF-IL6 in transfection and by IL-6 induction ( Fig. 2 and 4) (64) . This raises the question of whether the cooperation of ElA with E1B for transformation can be substituted by NF-IL6 or the IL-6 signaling pathway. Although the other members of the C/EBP family have been extensively studied in the terminal differentiation of hepatocytes and adipocytes, they have not previously been shown to function as repressors. The NF-IL6 recognition sequence is also present in the promoters and enhancers of cellular genes, including the immunoglobulin enhancer, which is activated or repressed by ElA depending on the cell type (5, 25) . Since immunoglobulin genes are regulated at the level of transcription during IL-6-induced terminal differentiation of B cells (57) , it is likely that NF-IL6 is pivotal in this regulatory pathway and that ElA may mimic the NF-IL6 function. As a cellular signaling pathway begins with the receptor for external stimuli, an understanding of the IL-6 signaling pathway and the extent of its overlap with ElA functions will undoubtedly give insights into the biological significance of regulation of ElA-responsive genes by NF-IL6.
